Summit Therapeutics (SMMT) Competitors

Summit Therapeutics (NASDAQ:SMMT) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, media sentiment, institutional ownership, community ranking and earnings.

Is SMMT or TAK more profitable?

Takeda Pharmaceutical has a net margin of 4.53% compared to Summit Therapeutics' net margin of 0.00%. Takeda Pharmaceutical's return on equity of 9.39% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Summit Therapeutics	N/A	-85.42%	-52.66%
Takeda Pharmaceutical	4.53%	9.39%	4.53%

Do institutionals & insiders have more ownership in SMMT or TAK?

4.6% of Summit Therapeutics shares are owned by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are owned by institutional investors. 84.9% of Summit Therapeutics shares are owned by company insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Does the MarketBeat Community believe in SMMT or TAK?

Summit Therapeutics received 212 more outperform votes than Takeda Pharmaceutical when rated by MarketBeat users. Likewise, 58.50% of users gave Summit Therapeutics an outperform vote while only 57.06% of users gave Takeda Pharmaceutical an outperform vote.

Company	Underperform	Outperform
Summit Therapeutics	Outperform Votes 313 58.50%	Underperform Votes 222 41.50%
Takeda Pharmaceutical	Outperform Votes 101 57.06%	Underperform Votes 76 42.94%

Which has better valuation and earnings, SMMT or TAK?

Takeda Pharmaceutical has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Summit Therapeutics	$700K	25,876.61	-$614.93M	-$0.34	-71.74
Takeda Pharmaceutical	$4.58T	0.01	$994.06M	$0.22	64.73

Does the media favor SMMT or TAK?

In the previous week, Takeda Pharmaceutical had 2 more articles in the media than Summit Therapeutics. MarketBeat recorded 10 mentions for Takeda Pharmaceutical and 8 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 1.42 beat Takeda Pharmaceutical's score of 1.35 indicating that Summit Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Summit Therapeutics	7 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Takeda Pharmaceutical	9 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts rate SMMT or TAK?

Summit Therapeutics currently has a consensus price target of $37.40, indicating a potential upside of 53.34%. Given Summit Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Summit Therapeutics is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Summit Therapeutics	0 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	3.09
Takeda Pharmaceutical	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has more volatility and risk, SMMT or TAK?

Summit Therapeutics has a beta of -0.94, suggesting that its stock price is 194% less volatile than the S&P 500. Comparatively, Takeda Pharmaceutical has a beta of 0.26, suggesting that its stock price is 74% less volatile than the S&P 500.

Summary

Takeda Pharmaceutical beats Summit Therapeutics on 10 of the 19 factors compared between the two stocks.